Company Filing History:
Years Active: 2021
Title: The Innovations of Mingzhen Li
Introduction
Mingzhen Li is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of innovative drug delivery systems. His work focuses on creating advanced linkers for antibody drug conjugates, which are crucial in targeted cancer therapies.
Latest Patents
Mingzhen Li holds a patent for a "Tridentate connexon and use thereof." This patent discloses a type of tridentate linker that can be utilized to prepare antibody drug conjugates. The tridentate linkers are represented by a specific formula, where L denotes an antibody, antibody fragment, or protein; T represents the tridentate linker part; A indicates a cleavable or noncleavable linker group; and D signifies the drug part. The structure of the tridentate linker part is defined by another formula, where W can be substituted aryl, heteroaryl, linear alkyl, cycloalkyl, heterocycloalkyl, or any combination thereof. This innovative approach has the potential to enhance the efficacy of therapeutic agents.
Career Highlights
Mingzhen Li is currently associated with Newbio Therapeutics, Inc., where he continues to push the boundaries of biopharmaceutical research. His expertise in linker technology has positioned him as a key player in the development of next-generation therapies. With a focus on improving drug delivery mechanisms, he aims to contribute to more effective treatment options for patients.
Collaborations
Mingzhen Li collaborates with notable colleagues, including Deqiang An and Nianhe Han. Their combined expertise fosters a dynamic research environment that encourages innovation and the advancement of biotechnological solutions.
Conclusion
Mingzhen Li's contributions to the field of biotechnology, particularly through his patent on tridentate linkers, exemplify the importance of innovation in drug development. His work at Newbio Therapeutics, Inc. continues to pave the way for advancements in targeted therapies.